Free Trial
NASDAQ:YARW

Yarrow Bioscience Q3 2026 Earnings Results & Report

Yarrow Bioscience logo
$18.87 -0.76 (-3.87%)
As of 11:29 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Yarrow Bioscience reported Q3 2026 earnings on November 12, 2026. The company reported EPS of -$0.43.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
8:00 AM ET

Yarrow Bioscience EPS Results

Actual EPS
-$0.43
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Yarrow Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Yarrow Bioscience Q3 2026 Earnings FAQ

Yarrow Bioscience (NASDAQ:YARW) reported earnings of -$0.43 per share for Q3 2026. The report was announced on Thursday, November 12, 2026.

Yarrow Bioscience Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Yarrow Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Yarrow Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Yarrow Bioscience and other key companies, straight to your email.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

View Yarrow Bioscience Profile